KalVista Pharmaceuticals, Inc. financial data

Symbol
KALV on Nasdaq
Location
Framingham, MA
Fiscal year end
30 April
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 684% % -12%
Return On Equity -232% % -147%
Return On Assets -75% % 12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50,523,274 shares 17%
Common Stock, Shares, Outstanding 50,542,711 shares 17%
Entity Public Float $440,082,646 USD 61%
Common Stock, Value, Issued $50,000 USD 16%
Weighted Average Number of Shares Outstanding, Basic 53,883,681 shares 16%
Weighted Average Number of Shares Outstanding, Diluted 53,883,681 shares 16%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $13,700,000 USD
Revenue from Contract with Customer, Excluding Assessed Tax $13,692,000 USD
Research and Development Expense $53,570,000 USD -42%
General and Administrative Expense $116,286,000 USD 114%
Operating Income (Loss) $205,359,000 USD -21%
Nonoperating Income (Expense) $430,000 USD -103%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $205,789,000 USD -21%
Income Tax Expense (Benefit) $7,706,000 USD
Net Income (Loss) Attributable to Parent $207,423,000 USD -37%
Earnings Per Share, Basic -4 USD/shares -11%
Earnings Per Share, Diluted -4 USD/shares -11%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $243,497,000 USD 486%
Inventory, Net $458,000 USD
Assets, Current $325,226,000 USD 114%
Property, Plant and Equipment, Net $3,190,000 USD 56%
Operating Lease, Right-of-Use Asset $9,096,000 USD 55%
Other Assets, Noncurrent $2,419,000 USD 265%
Assets $339,931,000 USD 111%
Accounts Payable, Current $8,074,000 USD 55%
Employee-related Liabilities, Current $10,997,000 USD 58%
Accrued Liabilities, Current $20,767,000 USD 35%
Contract with Customer, Liability, Current $11,512,000 USD
Liabilities, Current $45,069,000 USD 103%
Operating Lease, Liability, Noncurrent $9,128,000 USD 110%
Liabilities $322,932,000 USD
Accumulated Other Comprehensive Income (Loss), Net of Tax $6,729,000 USD -149%
Retained Earnings (Accumulated Deficit) $739,098,000 USD -34%
Stockholders' Equity Attributable to Parent $16,999,000 USD -89%
Liabilities and Equity $339,931,000 USD 111%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $54,502,000 USD -36%
Net Cash Provided by (Used in) Financing Activities $23,210,000 USD 674%
Net Cash Provided by (Used in) Investing Activities $21,261,000 USD -43%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 50,542,711 shares 17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $7,308,000 USD -12486%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $124,964,000 USD 292%
Deferred Tax Assets, Valuation Allowance $65,064,000 USD 11%
Deferred Tax Assets, Gross $66,184,000 USD 10%
Operating Lease, Liability $10,557,000 USD
Payments to Acquire Property, Plant, and Equipment $290,000 USD 1281%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $217,313,000 USD -43%
Lessee, Operating Lease, Liability, to be Paid $16,414,000 USD 138%
Property, Plant and Equipment, Gross $6,735,000 USD 13%
Operating Lease, Liability, Current $1,429,000 USD -1%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,735,000 USD 71%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,317,000 USD 33%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5,857,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,204,000 USD 38%
Deferred Tax Assets, Operating Loss Carryforwards $54,638,000 USD 8.9%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,226,000 USD 59%
Depreciation, Depletion and Amortization $252,000 USD 12%
Deferred Tax Assets, Net of Valuation Allowance $1,120,000 USD -22%
Share-based Payment Arrangement, Expense $5,379,000 USD 77%